Your browser is no longer supported. Please, upgrade your browser.
CASI Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own3.40% Shs Outstand124.83M Perf Week-10.00%
Market Cap215.19M Forward P/E- EPS next Y-0.29 Insider Trans168.34% Shs Float98.79M Perf Month0.66%
Income-53.70M PEG- EPS next Q-0.07 Inst Own38.10% Short Float5.40% Perf Quarter-36.78%
Sales17.50M P/S12.30 EPS this Y8.90% Inst Trans27.72% Short Ratio2.60 Perf Half Y-41.38%
Book/sh0.80 P/B1.91 EPS next Y3.30% ROA-42.80% Target Price- Perf Year-39.04%
Cash/sh0.56 P/C2.72 EPS next 5Y- ROE-63.90% 52W Range1.32 - 3.90 Perf YTD-48.14%
Dividend- P/FCF- EPS past 5Y-14.50% ROI-62.20% 52W High-60.77% Beta0.14
Dividend %- Quick Ratio8.60 Sales past 5Y216.50% Gross Margin50.50% 52W Low15.91% ATR0.09
Employees118 Current Ratio8.90 Sales Q/Q67.60% Oper. Margin- RSI (14)40.54 Volatility5.42% 5.07%
OptionableNo Debt/Eq0.02 EPS Q/Q-30.10% Profit Margin- Rel Volume0.70 Prev Close1.60
ShortableYes LT Debt/Eq0.00 EarningsMay 13 BMO Payout- Avg Volume2.05M Price1.53
Recom1.50 SMA20-6.36% SMA50-8.38% SMA200-29.88% Volume1,439,623 Change-4.38%
May-18-21Initiated BTIG Research Buy $4
Apr-26-21Initiated Mizuho Buy $3.80
Oct-23-20Initiated Oppenheimer Outperform $5
Sep-22-16Initiated Maxim Group Buy $4
Oct-29-15Resumed H.C. Wainwright Buy $2.50 → $3
Jun-23-15Initiated H.C. Wainwright Buy $2.50
Jun-10-21 07:00AM  
May-27-21 07:00AM  
May-17-21 10:20AM  
May-13-21 07:00AM  
May-11-21 07:00AM  
Apr-28-21 10:39AM  
Apr-26-21 02:11AM  
Mar-30-21 07:00AM  
Mar-24-21 03:57PM  
Mar-23-21 04:01PM  
Mar-11-21 04:30PM  
Mar-08-21 10:17AM  
Feb-25-21 12:08AM  
Feb-16-21 07:00AM  
Jan-28-21 07:00AM  
Jan-21-21 07:00AM  
Jan-11-21 12:17AM  
Jan-08-21 07:00AM  
Dec-23-20 07:00AM  
Dec-16-20 07:00AM  
Dec-12-20 02:20PM  
Nov-30-20 09:05AM  
Nov-26-20 11:16PM  
Nov-18-20 09:00PM  
Nov-09-20 10:30PM  
Nov-06-20 06:14AM  
Nov-05-20 07:00AM  
Oct-27-20 07:00AM  
Oct-02-20 07:00AM  
Sep-29-20 07:00AM  
Sep-11-20 07:00AM  
Sep-07-20 08:28AM  
Aug-26-20 05:31AM  
Aug-11-20 11:30AM  
Aug-10-20 07:29AM  
Jul-22-20 09:05AM  
Jul-21-20 04:01PM  
Jul-09-20 09:39AM  
Jun-08-20 07:00AM  
Jun-02-20 07:00AM  
May-31-20 05:38PM  
May-25-20 06:14AM  
May-14-20 06:47AM  
May-12-20 06:43AM  
May-11-20 07:00AM  
May-08-20 09:05AM  
Apr-07-20 07:00AM  
Mar-31-20 07:05AM  
Mar-29-20 08:08AM  
Mar-16-20 07:00AM  
Mar-02-20 06:03AM  
Feb-21-20 07:46AM  
Feb-07-20 10:49AM  
Feb-04-20 07:51AM  
Jan-26-20 08:33AM  
Dec-20-19 05:27AM  
Dec-03-19 09:00PM  
Nov-14-19 05:17AM  
Nov-12-19 07:00AM  
Nov-07-19 07:00AM  
Nov-06-19 09:33AM  
Sep-19-19 07:00AM  
Sep-16-19 06:00AM  
Sep-03-19 07:00AM  
Aug-20-19 07:15PM  
Aug-19-19 12:22PM  
Aug-16-19 10:20AM  
Aug-15-19 07:15PM  
Aug-12-19 03:03PM  
Aug-09-19 07:00AM  
Jul-31-19 10:44AM  
Jun-17-19 07:00AM  
Jun-03-19 07:00AM  
May-20-19 09:45AM  
May-15-19 07:00AM  
May-13-19 10:00AM  
May-03-19 08:42AM  
Apr-18-19 04:15PM  
Apr-17-19 07:00AM  
Apr-02-19 07:00AM  
Mar-29-19 07:00AM  
Mar-13-19 07:00AM  
Mar-07-19 07:00AM  
Feb-26-19 08:14AM  
Feb-20-19 08:15AM  
Feb-19-19 07:00AM  
Feb-06-19 07:00AM  
Dec-28-18 11:45AM  
Dec-26-18 09:32AM  
Dec-03-18 09:15AM  
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
He Wei-WuChairman and CEOMar 26Buy2.053,000,0006,150,0003,000,000Mar 30 04:52 PM
Xu WeihaoChief Financial OfficerDec 17Buy2.634,00010,53710,000Dec 18 04:05 PM
Xu WeihaoChief Financial OfficerDec 16Buy2.442,0004,8806,000Dec 18 04:05 PM
He Wei-WuChairman and CEONov 23Buy2.18100,000218,0005,063,994Nov 24 05:39 PM
He Wei-WuChairman and CEONov 20Buy2.12127,471270,2394,963,994Nov 24 05:39 PM
Zhang LarryPresidentJul 22Buy1.9020,15338,29120,153Jul 24 04:05 PM
He Wei-WuChairman and CEOJul 22Buy1.901,200,0002,280,0007,532,347Jul 24 04:03 PM
He Wei-WuChairman and CEOJul 22Buy1.902,952,4265,609,6094,836,523Jul 24 04:03 PM